Mankind Pharma Limited — Others, 24-01-2025: Copy of Newspaper Publication

Mankind Pharma Limited has announced a board meeting to discuss the consolidated financial results for the quarter and nine months ended December 31, 2024. The company reported revenue from operations of ₹3,230 cr for the quarter, up from ₹2,606.95 cr year-over-year. Profit after tax for the quarter stood at ₹384.52 cr, with total comprehensive income of ₹395.45 cr. This shows a healthy growth trajectory, reinforcing Mankind's strong market position and operational efficiency. Investors may view this as a positive outlook for the company’s growth potential moving forward.